ABSTRACT OBJECTIVE: To determine in vitro antibacterial activity of commercially available skin, wound, and skin/wound cleansers at cell-safe (nontoxic) concentrations.
INTRODUCTION
Chronic nonhealing wounds, such as venous ulcers, diabetic ulcers, and pressure ulcers, cause tremendous patient suffering. Treatment of such wounds presents a serious unmet medical need. Strategies that optimize the tissue repair have evolved with advances in understanding of the wound healing process. 1 Successful wound healing begins with proper wound bed preparation. There are 4 components to wound bed preparation, all of which address the different pathophysiological abnormalities underlying chronic wounds. These components form a framework that has been named TIME (tissue management, inflammation and infection control, moisture imbalance and epithelial [edge] advancement). 2 Infection control is an important part of the TIME framework. Evidence shows that a bacterial burden of 10 6 microorganisms or more per gram of tissue seriously impairs healing. 3 Bacteria may stimulate a persisting inflammation leading to the production of inflammatory mediators and proteolytic enzymes. Among many other effects, this causes extracellular matrix degradation and inhibition of reepithelialization. 4 Recently, there has been increased interest in the role of biofilms in impaired healing. 5, 6 A wound cleanser without antimicrobial and antibiofilm activity, such as saline, may not be ideal for wound care. 7 Epithelial advancement, another critical component of the TIME framework, requires activity of fibroblasts 8, 9 and keratinocytes, 10 which may be hampered by aggressive and toxic wound cleansers. For example, Cetrimidebased cleansing agents are not recommended as their cytotoxic action may impede healing. 11 When such products are used, epithelial cells are killed alongside bacteria. The problem arises from the fact that bacteria recolonize and multiply every 30 to 60 minutes, 12 whereas epithelial cells can only reproduce every 24 hours. 13 As a result, bacteria always win, and wound healing is delayed. An ideal wound cleanser provides periodic reduction of bacterial contamination and removal of debris without adversely impacting cellular activities vital to the wound healing process. Therefore, one of the first steps in a comprehensive strategy for evaluating wound care products is to study their potential cytotoxicity for relevant cell types. In vitro models for cytotoxicity evaluation have included monolayer cultures of human fibroblasts, 15Y19 mouse fibroblasts, 20 keratinocytes, 15, 21, 22 and polymorphonuclear leukocytes. 23 In this study, the authors determined the noncytotoxic, safe concentration of all 20 important and widely used skin/wound cleansers and compared the microbicidal activity of these cleansers at their noncytotoxic concentrations.
MATERIALS AND METHODS

Test Agents
Twenty commercial skin, wound, and skin/wound cleansers were evaluated. Materials were obtained from manufacturers or distributors (Table 1) . For the initial test, materials were used in their original concentrations.
Cells and Testing
L929 mouse fibroblasts were obtained from the American Type Culture Collection (ATCC CCL-1). Cytotoxicity was evaluated by modification of methods described by Wilson et al. 15 L929
cells were briefly seeded into 96-well plates at a density of 20,000 cells/well, allowed to adhere in >-minimum essential medium (>-MEM) (containing 10% fetal bovine serum and 2 mM l-glutamine for 24 hours), and cultured under the same conditions until they were ready for use. After 24 hours, media was removed from the cells by aspiration. The cells were then exposed to the various test agents for 30 minutes at 37-C and assayed for viability.
Cell viability was determined using CellTiter 96 nonradioactive cell proliferation assay (Promega, Madison, Wisconsin). The agents were serially diluted 1:10 with phosphate-buffered saline (PBS), and each dilution was tested for cytotoxicity until the results of the cells exposed to the diluted test solutions were similar to those of cells exposed to PBS alone. Testing at each dilution was performed in duplicate. The CellTiter 96 proliferation assay is composed of a tetrazolium compound, (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (MTS), and an electron coupling reagent phenazine methosulfate. MTS is reduced by cells into a formazan product, which is soluble in tissue culture medium. The absorbance of formazan at 490 nm can be measured directly without additional processing.
Time-Kill Bacterial Assay
Time-kill kinetics of each test agent at nontoxic dilution in PBS was tested against methicillin-resistant Staphylococcus aureus (MRSA) ATCC 33591 (10 8 
colony-forming units [CFU]/mL).
The nontoxic dilution for each product was based on MTS cell proliferation/viability assay results and defined as the dilution required for generating experimental cell viability to be 85% of controls (cells exposed only to >-MEM medium). Time points included 1, 5, 15, 30, and 60 minutes and 4 and 24 hours. At each time point, bacteria were serially diluted, plated, incubated at 37-C, and enumerated for CFU counts. A time point at which at least 10,000 reduction in CFU counts was observed (from 10 8 CFU/mL to 10 4 CFU/mL) was defined as time to 4-log kill and determined for each skin/wound cleanser. 
RESULTS
The cytotoxicity dilution and antibacterial timeYkill results are shown in Table 2 . In order to reach a nontoxic concentration for mouse fibroblasts, each skin/wound cleanser had to undergo 0-to 10,000-fold dilutions ( The time to kill at the nontoxic dilution of NeutroPhase (10-fold dilution) was less than 1 minute, followed by Puracyn (10-fold dilution) at 30 minutes. The time to kill at nontoxic dilutions of all other commercially available wound cleansers was greater than or equal to 24 hours (Table 2) .
DISCUSSION
An ideal wound cleanser should have minimal cytotoxicity together with potent and rapid antimicrobial activity. Potent wound cleansers with a high toxicity index (eg, Betadine, chlorhexidine, polyhexamethylene biguanide) will likely have deleterious effects to living tissue. At the same time, a nontoxic wound cleanser (eg, saline, Shur-Clens, Restore Wound Cleanser) without antimicrobial activity will likely provide minimal reduction in bacterial burden (Table 3) .
This in vitro study demonstrates that many wound and skin cleansers may be toxic to fibroblastsVone of the key cells in wound repairVand suggests that these cleansers might also be toxic to other cells. When diluted to ''cell-safe'' concentrations, most of the cleansers' lost antibacterial activity was reflected by the length of time needed to reduce the growth of S aureus. Although there is not a well-defined rule to quantify the relationship between the in vitro cell toxicity of a skin/wound cleanser and its effects on healing wounds, it has been shown that in vitro cell toxicity correlates with retardation of healing. 15 For example, application of SAF-Clens AF and Shur-Clens into a full-thickness guinea pig dorsum skin wounds resulted in a healing process that did not differ from healing in wounds in which saline was applied. The application of Betadine Surgical Scrub resulted in significantly slower dermal and epidermal healing. 24 These findings correlate with the results of in vitro fibroblast model where SAF-Clens AF and Shur-Clens were found to be nontoxic to fibroblasts at commercial concentrations, whereas the povidone-iodine (Betadine Surgical Scrub) showed the highest cytotoxicity.
The results of these studies offer some guidance for wound care in the complex circumstances encountered in most wounds. Several of the cleansers studied are not toxic to cells even in vitro, whereas a single 10-fold dilution is sufficient to render another group nontoxic. Depending on the goals envisioned for the cleanser treatment, these groups might well be considered best from a safety point of view. In this category, based on their microbiologic effect in these studies, 2 agents, NeutroPhase and Puracyn (or the similar product Dermacyn), separate out as the others required over 24 hours to reach a 4-log reduction in S aureus. NeutroPhase required a less than 1-minute exposure, and Puracyn or Dermacyn required a 30-minute exposure to reach the same reduction. NeutroPhase is a pure hypochlorous acid (HOCl, 0.01%) solution in 0.9% saline at pH 4, whereas Dermacyn and Puracyn, according to their labels, contain electrolyzed water (99.97%), sodium chloride (NaCl) 0.023%, sodium hypochlorite (NaOCl) 0.004%, and hypochlorous acid 0.003%. Hypochlorous acid is a naturally occurring well-known broad-spectrum, 25, 26 fast-acting 27 antimicrobial agent produced by neutrophils and monocytes 28 as part of the innate immune system's response to infection. In addition to being able to directly penetrate bacteria, spores, and amoeba cysts, hypochlorous acid has been shown to disrupt biofilm.
29Y32
Hypochlorous acid has also been described as being 80 to 100 times more potent as a germicide than the equivalent molar ratio of hypochlorite anion. 33 This is due to the fact that pure hypochlorous acid as an uncharged species can penetrate microbial cells and spore walls, whereas the charged hypochlorite anion cannot penetrate cell walls. Previous reports show that hypochlorous acid has broad-spectrum antibacterial activity against grampositive and gram-negative pathogens including drug-resistant bacteria such as MRSA, vancomycin-intermediate resistant S aureus, and mupirocin-resistant S aureus with a minimal bactericidal concentration ranging from 0.1 to 2.8 Kg/mL and also demonstrated fungicidal activity against Candida albicans and Aspergillus niger. 17 Higher concentration of free HOCl in NeutroPhase compared with Dermacyn or Puracyn likely explains faster antibacterial activity of NeutroPhase. The rapid activity of NeutroPhase seen in these studies is reflective of its potent in vivo activity in a rat chronic wound model. 34 Although safe at concentrations offered in NeutroPhase, hypochlorous acid and hypochlorite anion may cause tissue necrosis and/or apoptosis at higher concentrations found in Dakin solution (0.5%).
35Y37
In this study, in vitro methods were used to evaluate the potentially deleterious effects of cleansers on wound healing as well as the likely antimicrobial activities of cleansers. The in vitro findings correlated with many in vivo studies and with clinical advice. The antimicrobial activity of 2 of the 19 agents studiedV NeutroPhase and PuracynVstood out. Both cleansers contained hypochlorous acid, a particularly-rapidly acting antimicrobial produced endogenously as part of the body's innate immune system. These studies should prove useful to clinicians developing wound care strategies and to those wishing to develop and expand in vitro methods to evaluate the potential effects of agents used for wound care. 
